LAVAL, Quebec, Jan. 30, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") today announced that it plans to hold a conference call and live webcast on Tuesday, February 28, 2017 at 8:00 a.m. ET. The Company will discuss fourth quarter and full year 2016 financial results, and announce 2017 guidance during the presentation. Related materials will be made available on the investor relations portion of the corporate website before the start of the conference call.

Conference Call Details



    Date         Tuesday, February 28, 2017

    Time         8:00 a.m. ET

    Webcast      http://ir.valeant.com/events-and-presentations

    Participant
     Event Dial-
     in          (877) 876-8393 (North America)

                 (443) 961-0178 (International)

    Participant
     Passcode                                                                                       63999208

    Replay Dial-
     in          (855) 859-2056 (North America)

                 (404) 537-3406 (International)

    Replay
     Passcode                                                   63999208 (replay available until 03/31/2017)

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Contact Information:
Elif McDonald
elif.mcdonald@valeant.com
514-856-3855
877-281-6642 (toll free)

Media:
Renée Soto or
Chris Kittredge/Jared Levy
Sard Verbinnen & Co.
212-687-8080

http://photos.prnewswire.com/prnvar/20101025/LA87217LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/valeant-to-hold-conference-call-to-present-fourth-quarter-and-full-year-2016-results-and-announce-2017-guidance-300398963.html

SOURCE Valeant Pharmaceuticals International, Inc.